Abstract The progression of tumours to malignancy is commonly considered to arise through lineal evolution, a process in which mutations conferring pro-oncogenic cellular phenotypes are acquired by a succession of ever-more dominant clones. However, this model is at odds with the persistent polyclonality observed in many cancers. We propose that an alternative mechanism for tumour progression, called interclonal cooperativity, is likely to play a role at stages of tumour progression when mutations cause microenvironmental changes, such as occur with epithelialmesenchymal transitions (EMTs). Interclonal cooperativity occurs when cancer cell-cancer cell interactions produce an emergent malignant phenotype from individually nonmalignant clones. In interclonal cooperativity, the oncogenic mutations occur in different clones within the tumour that complement each other and cooperate in order to drive progression. This reconciles the accepted genetic and evolutionary basis of cancers with the observed polyclonality in tumours. Here, we provide a conceptual basis for examining the importance of cancer cell-cancer cell interactions to the behaviour of tumours and propose specific mechanisms by which clonal diversity in tumours, including that provided by EMTs, can drive the progression of tumours to malignancy.
Carcinogenesis progresses in clinical stages that are reflected in discrete behavioral (phenotypic) changes in the cells that give rise to the cancer. Underlying this progression from normal tissue to pre-malignant tumour to malignant tumour is the acquisition of discrete changes in the genomes of the cells that make up the tumour [1] . It is generally accepted that these genotypic changes (mutations), in concert with the selection of cells with an advantage in survival and proliferation, is what drives tumour progression. They may include essentially irreversible changes such as substitutions, deletions, amplifications and translocations, as well as metastable epigenetic features such as methylation and chromatin structural signatures. The mutations that underlie the acquisition of malignant characteristics in tumour cells are generally considered to arise within a succession of evermore dominant clones [2, 3] , a process that we will refer to as lineal evolution. Lineal evolution predicts that the genotypic changes that give rise to the malignant phenotypic changes are cumulative within the clone that progresses to full malignancy.
Each time a tumour cell undergoes a mutation, it adds genetic diversity to the tumour cell population, because it becomes genetically distinct from its parent cell, thereby creating a new clone. According to lineal evolution, if a mutation is not seriously deleterious to the survival and replication of the cell, this added genetic diversity will persist until either the resultant clone is outgrown by other clones under some sort of selection pressure, such as nutrient limitation, or itself outgrows other clones, thereby dominating the tumour [2, 3] . However, during the time before selection eliminates it, and for as long as no selection pressure is introduced to discriminate against it, the added genetic diversity persists. A direct consequence of this is added phenotypic diversity, at least until selection of a dominant clone occurs.
Phenotypic changes in epithelial cells caused by mutations can result in an epithelial-mesenchymal transition (EMT), in which epithelial differentiation characteristics of gene expression, topology and behaviour are lost and replaced by those more commonly associated with mesenchymal cells [4] [5] [6] . However, cancer is increasingly being appreciated as a disease of stem cells, and part of its phenotypic heterogeneity may be caused by the inappropriate implementation of normal differentiation programs, which can have lasting phenotypic consequences via epigenetic mechanisms. This differentiation program can be initiated by upstream genetic alterations and/or by microenvironmental influences [4, 7, 8] and can be reversible [9, 10] .
Mutations can produce either cell-autonomous or microenvironmental phenotypes
The phenotypes arising from mutations in a cell lineage that allow a tumour to form or to progress to malignancy can be either cell-autonomous, having no immediate effect on the cells surrounding it, or microenvironmental, affecting both the cell bearing the mutation and its neighbouring cells and surrounding extracellular matrix (ECM). Examples of phenotypes normally considered to be cellautonomous are resistance to stimuli that induce senescence, apoptosis or terminal differentiation, escape from cell-cycle controls and loss of DNA-repair mechanisms, all of which generally occur early in tumour development.
However, cell-autonomous phenotypes can also contribute to cancer pathogenesis in later stages e.g. the acquisition of multidrug resistance through point mutation or amplification of MDR1, which encodes a drug efflux pump [11, 12] . In keeping with the lineal evolution model, the net effect of each of these cell-autonomous phenotypes is to confer upon the clone that acquires them an enhanced ability to proliferate in situ, even following therapeutic intervention. This growth advantage over its neighbours allows the clone to dominate the tumour. In the case of losing the ability to repair DNA, it also gives rise to a higher rate of mutations in subsequent generations, which makes it more likely that this clone will acquire beneficial (to the survival of its progeny), as well as deleterious, mutations [3] .
A microenvironmental phenotype is a consequence of a mutation that affects not just the cell that bears the mutation, but also the neighbouring cells and nearby ECM that together constitute its microenvironment. Just as a mutation in a cell can alter its effect on its microenvironment, the microenvironment can, in turn, alter that cell [13] . It is the cellular component of the microenvironment that will be focussed upon here. In tumour cells, pro-oncogenic microenvironmental phenotypes arise from mutations that cause the production of a factor that confers advantage on other, nearby cells, as well as on the cell that makes the factor.
Invasion is by definition the spread of cancer cells into their local environment and so, not surprisingly, many of the cellular phenotypes that are associated with invasiveness are microenvironmental in nature, often relying on the secretion of factors into the extracellular space. However, other phenotypes may also be microenvironmental. Examples of microenvironmental phenotypes are the angiogenic phenotype, the pro-inflammatory phenotype and the ECM destructive phenotype. Thus, the acquisition of a mutation that causes a cancer cell to secrete an angiogenic factor will promote an efficient vasculature that will provide an enhanced nutrient supply and the opportunity to grow larger, not only to the cell that makes the factor, but to all other cells in the vicinity, including nonmutant cells. A mutation that causes the release of leukocyte attracting or activating molecules will encourage an inflammatory environment not just for the cancer cells that harbour that mutation, but also for nearby cancer cells that lack it. Similarly, the acquisition of a mutation that causes a cell to release excessive amounts of ECM-degrading enzymes will result in a more porous ECM that will provide an enhanced opportunity to migrate unimpeded into surrounding tissues, not only to the cell that makes the enzymes, but also to all other cells in the vicinity. Some phenotypes can be either cell-autonomous or microenvironmental, depending on the genes that are mutated (Table 1) . For example, a mutation that provides drug resistance by up-regulating the expression of a gene such as MDR1, which pumps cytotoxic drugs from the cytoplasm into the extracellular space, would be cell-autonomous, since it would not benefit any of the cells surrounding it [12] . In contrast, a mutation that allowed a cell to inactivate a chemotherapeutic drug metabolically, and in so doing cause it to be locally depleted below a therapeutic concentration [14] , would benefit non-mutant cells in the vicinity, and so the mutation would be microenvironmental. A recent study using genetically mosaic mice showed that mutations in a single gene can lead to either a cellautonomous or a microenvironmental phenotype, depending on the tissue in which they arise [15] .
Genetic and phenotypic diversity can persist in tumours
Despite the general acceptance of lineal evolution leading to clonal dominance and even monoclonality in neoplasia, genetic diversity (polyclonality) is a common characteristic of tumours [16, 17] . Genetic diversity has been identified using a variety of molecular and cytogenetic methods in tumours of the breast [18, 19] and other tissues [20] [21] [22] [23] [24] [25] [26] [27] . Many of the early studies from which monoclonality gained general acceptance may have missed the presence of additional clones due to technical limitations: a lack of sensitivity in detecting numerically minor clones, an inability to sample small enough areas within tumours in which clones intermingle, or the use of mosaic gene expression of inappropriately large patch size [16] . In cases where the sequencing of genes in gross tumour specimens has been unable to demonstrate any genetic heterogeneity, it has nevertheless been demonstrated by using sequencing in conjunction with microdissection and denaturing high pressure liquid chromatography analysis [22, [28] [29] [30] . Such analyses were not used in earlier studies of tumour clonality and still are not used routinely in pathology laboratories.
Polyclonality within tumours could arise in three ways ( Fig. 1) , each of them distinct from lineal evolution (lineage A) and resulting in co-dominant, cooperating clones. A single normal cell could give rise to a clone that cooperates with a mutant daughter clone, allowing both to be retained in the malignancy (lineage B). Alternatively, a single normal cell could mutate into an abnormal precursor clone that then bifurcates through distinct subsequent mutations into separate derivative clones (lineage C). Alternatively, two or more normal somatic cells could mutate independently in parallel and their progeny would mix to form the tumour (lineage D). It is not known in general which of these mechanisms most frequently gives rise to polyclonality. Studies using mosaicism of X-chromosome inactivation in females have been used to address this issue and many have concluded that tumours have their origin in a single normal cell. However, this conclusion cannot be drawn from such studies with any confidence because of a heavy bias towards monoclonality, due to the large mosaic patch size of X-chromosome inactivation in relation to the size of the tumours [31] . Despite this bias towards monoclonality, this method has sometimes identified polyclonality arising from two or more normal cells in tumours of the breast [32] . This form of polyclonality was also demonstrated in multiple colonic adenomas from a rare XO/XY mosaic human who also had familial adenomatous polyposis [23] , and in experimentally induced papillomas in chimeric mice [20] , where the smaller patch sizes in both cases gave less bias towards monoclonality. A definitive answer to how often polyclonality has its origins in one or more clones of normal cells may await a novel analytical or experimental approach. It is often assumed that if a strong enough selection pressure is applied to a tumour cell population, then monoclonality will necessarily follow. However, this assumption is challenged both by the occurrence of polyclonal tumours in advanced stage cancers and by reasoned argument. Whether the number of normal cells from which polyclonal tumours originate is one or more than one, it is possible that two or more clones could persist in a tumour, even under strong selection pressure, through processes analogous to mutualism in the evolution of whole organisms. Moreover, cancer is likely to provide the circumstances under which this co-dominance can take place, as described below.
Cancer cell-cancer cell interactions are a consequence of microenvironmental phenotypes Together, the two aforementioned characteristics of tumours-the presence of microenvironmental phenotypes within a tumour, and the phenotypic diversity of cancer cells within it-provide the potential for events to occur that are rarely considered in studies of carcinogenesis: cancer cell-cancer cell interactions. Interactions can occur between diverse subpopulations of cancer cells that cannot take place in a homogeneous population. In cases where interactions between two or more phenotypically distinct clones produce an emergent malignant phenotype, interclonal cooperativity occurs [33, 34] . Interclonal cooperativity is defined as the state in which two or more neoplastic clones display a more malignant phenotype in coexistence than in isolation [33, 34] . Thus, clones-none of which are intrinsically invasive and metastatic-can interact when they are in proximity to one another in order to become invasive and metastatic. In the interclonal cooperativity model of tumour progression, not all of the mutations needed for progression are cumulative within a clone, in contrast to the lineal evolution model (Fig. 1) . Moreover, as observed previously [33] and discussed below, even a small minority of phenotypically distinct cells can have an enormous impact on the behaviour of the population as a whole.
Interclonal cooperativity is illustrated by the production of collagen-degrading activity by the BC1 rat mammary carcinoma cell line in vitro. BC1 is composed of two phenotypically distinct cell populations: ''E-cells'', which have retained epithelial differentiation characteristics, and ''M-cells'' which are metaplastic, having undergone an EMT. Alone, each cell type produces little collagendegrading activity. However, when co-cultured, they produce a large amount of collagen-degrading activity [33, 34] . The fact that both E-cells and M-cells are needed for the production of collagen-degrading activity first drew attention to the possibility that interclonal cooperativity (originally called biclonal cooperativity) could play a role in the progression of tumours to malignancy. The molecular basis underlying this cooperativity is the secretion of factors by the E-cells that stimulate secretion of collagendegrading matrix metalloproteinases by the M-cells. The Ecells also secrete factors that stimulate growth and attachment of M-cells, whereas the M-cells make large amounts of multidrug resistance proteins [34, 35] .
There is also evidence that interclonal cooperativity contributes to metastasis in vivo. The BC1 cell line was injected into syngeneic animals to grow tumours, and cell lines (''LN'') were established from their lymph node metastases [34] . Lineal evolution predicts that the metastases from the LN cell lines should be as large or larger than those from the original BC1 cells, because they have been selected for the ability to metastasise to the lymph nodes. However, the experimental data do not support this. Tumours derived from those LN cell lines produced metastases that were significantly smaller than those produced by the original BC1 cell line grown under identical conditions, whereas the primary tumours did not differ significantly in size (Fig. 2) . These data are consistent with an interclonal cooperativity taking place in which there exists a subpopulation of cells that facilitates the metastasis of other cells within the primary tumour, but that does not itself metastasise. Thus, the population of cells that has metastasised produces smaller metastases due to the lack of non-metastatic facilitator cells in the primary tumours in the LN cell lines.
A contribution of interclonal cooperativity to metastasis does not require that cells of the primary tumour communicate with cells of the secondary tumour; only that communication between cells within the primary tumour takes place. Metastasis is a multi-stage process, several stages of which interclonal cooperativity could contribute to. For example, invasion of the vasculature and detachment from the primary tumour mass could require the production of paracrine factors, as described above. If cells that entered the circulation were competent to survive and grow at the secondary site, then there would be no need for ongoing exposure to the paracrine factors for metastasis to occur. Alternatively, it is conceivable that growth of a clone at a secondary site (e.g. lymph node) could require factors that could be provided by other cancer clones through paracrine secretion or cell-cell contact, but not by the non-cancer cells normally resident at the secondary site. In this case, even though the clone had reached the secondary site, it would remain dormant as an occult metastasis until either cells of a complementary clone also reached its vicinity or a subsequent complementary mutation occurred. A scenario similar to this was proposed by Israel [36] to explain occult metastases, although it was not clear whether the source of the hypothetical paracrine factor was stromal cells or other cancer cells.
Factors affecting the impact of a microenvironmental phenotype on cancer cell-cancer cell interactions
The space in which a microenvironmental phenotype of a cell can affect other cells is its field of influence, and is determined by the range over which the factors produced by that cell are active (Fig. 3) . Key to microenvironmental phenotypes is the ability of the cell to communicate the phenotype to its neighbours. This is most obviously done by the release of diffusible factors that mediate the phenotype, but also could be done by direct cell-cell signalling via cell-surface receptor-ligand pairs and cytoplasmic continua, or by modifying the ECM in such a way that it lays down signals for cells that encounter it subsequently via plasma membrane extrusions or gross motility in order to alter their behaviour.
The strength of a phenotypic field of influence will depend on the nature and amount of the phenotypeconferring factor and its interactions with the microenvironment. For example, if a high-motility phenotype is conferred on a cell by a mutation (MOT+) that causes it to release self-saturating amounts of a chemokine, then the strength of its field of influence diminishes with the square of the distance from the cell that makes it, in a classical diffusion manner: the further that a neighbouring cell that lacks the mutation is located from the source of the chemokine, the less it will benefit from it. However, a consequence of the chemokine will be the dispersal of the cells that make it, because they will be exposed to the highest concentration. This dispersal will tend to ensure that other, non-mutant clones within the tumour are never too far from a MOT+ cell, and so all cells within the tumour might end up being within a strong field of influence of the clone. This would be mutually antagonistic with the cell type partitioning effects that can be conferred by homotypic cell-cell adhesion molecules (discussed below). This mixing of the mutant clone with other clones in the tumour will be accentuated if the chemokine is also chemotactic. The chemotactic feature will have no effect on the direction of migration of the mutant cell that produces the factor, because it is at the highest concentration of it; only motility will be increased. However, non-mutant ) from BC1 or LN cell lines derived from BC1 lymph node metastases were injected into the footpad of recipient syngeneic rats and allowed to grow for 40 days, at which time the animals were euthanased and their popliteal lymph node metastases and primary tumours were weighed. The tumour masses and their medians are shown. **P \ 0.01 by Mann-Whitney U-test Fig. 3 The number of cells lying within the field of influence of a microenvironmental phenotype. A cancer cell in a tumour (grey) acquires a mutation that causes it to secrete a factor such that its concentration 10 cell diameters (10D) away is just high enough to exert its effect on neighbouring cancer cells. Beyond that, the concentration is too low. Thus, cells located entirely within a sphere of 11.5D radius will contact a sufficiently high concentration of the factor to be affected by it. Any cell entirely within this spherical field of influence that requires the factor in order to progress to malignancy will be able to do so-not just the cell that secretes the factor cells within the field of influence will tend to migrate towards the mutant cells, where the concentration of chemokine is at its highest. A consequence of this is that when the mutant clone invades surrounding tissues, it will tend to drag a cohort of non-mutant cells with it. Another consequence is a rapid blending of the tumour population, with the MOT+ clone becoming dispersed amongst MOTclones. This blending would make the recognition of polyclonality using gross histological or genetic procedures extremely difficult. A longer-term effect might be the selection of MOT-clones that acquire mutations that cause them to respond more strongly to the chemokine e.g. by up-regulating chemokine receptors. This would increase their genetic distance and phenotypic difference from the MOT+ clone, on which no such selection pressure would exist, thereby increasing tumour cell diversity even further.
The field of influence may also exhibit threshold effects. A special case in point is where direct cell-cell contact is responsible for communicating the phenotype arising from a mutation in a cell to the cells that surround it. The field of influence will extend to exactly one cell diameter outside of the mutant cell (i.e. 1.5 cell diameters from the centre of the cell). Inside that, non-mutant tumour cells benefit from the phenotype of the mutant cell; outside, they do not. Phenotypes mediated by mutation-induced diffusible factors can also give rise to threshold effects. For example, consider the situation in which penetration of the ECM is rate limiting for the expansion of a tumour, and pores of a certain size must be made in the ECM through the action of ECM-degrading enzymes in order for tumour cells to invade. When a mutation (DEG+) arises that causes the cells to release diffusible ECM-degrading enzymes, the porosity of the ECM near the mutant cell will increase to the point where the cell is able to migrate through it. Because the enzymes are diffusible, they will degrade the ECM further from the cell, also, albeit to a lesser extent, due to the concentration of enzymes diminishing with distance from the cell. As a consequence of the gradient of ECM-degrading enzymes radiating from the DEG+ cell, a gradient of ECM porosity is established, with the ECM closest to the DEG+ cell being most porous. As one moves further from a cell, a distance from the DEG+ cell is reached where the porosity of ECM is just insufficient for cells to be able to migrate through it. Neighbouring DEGcells within this distance will be able to invade the ECM, whereas those outside this distance will be unable. The concentrations of diffusible factors would be expected to drop to zero where blood or lymphatic vasculature is encountered, because it would diffuse into the vascular fluid and be carried away.
Combinations of gradients and thresholds also have the potential to occur e.g. where a phenotype is mediated by a mutation that causes the release of a diffusible factor that can be inactivated by binding irreversibly to an inhibitor that is present in the tissues. In this case, the strength of the field of influence will diminish with distance from the mutant cell until its concentration is equal to that of the inhibitor, when it becomes zero. Molecules that compete for these inhibitors, activators or co-factors could also regulate the field of influence of a phenotype, and these might be affected by other mutations. Clearly, as the number of mutations and/or extracellular factors involved increase above a very few, the complexity of the interactions makes accurate predictions of tumour behaviour based on intuition unreliable; mathematical modelling becomes essential [37] .
The contribution of EMT to cancer cell diversity and its microenvironmental consequences
EMT is an attractive mechanism for contributing to interclonal cooperativity in tumours because the phenotypic changes that it induces are so dramatic, and because many of them are microenvironmental in nature. Mesenchymalepithelial interactions have profound effects during normal development [38] and some of these might occur between tumour cells that have undergone an EMT and those that have retained epithelial differentiation characteristics, thereby contributing to malignancy. Indeed, EMT-like changes have been observed in cancers of the breast and other tissues that are in the process of invading and metastasising [5, 39] . The contribution of EMT to the heterogeneity of carcinomas is probably underestimated. When the cancer cell component of carcinomas is identified using mainly morphological criteria or epithelial differentiation markers, there is a possibility that cancer cells that have undergone an EMT are overlooked and considered erroneously to be non-malignant ''stromal'' cells, particularly when they constitute a numerically minor component of the tumour cell population. As demonstrated in the BC1 model [33] a minor subpopulation of cells that have undergone an EMT, constituting only 10% of the total, can have a marked effect on the ECM-degrading activity of the cancer cell population as a whole. The lower limit of the size of this minority population that confers an ECM-degrading activity on the population as a whole was not determined in that study, but may be even lower than 10%, which would make them even more likely to be overlooked or misidentified. The immortalised NMuMG mouse mammary cell line also displays heterogeneity, both in baseline morphology and in EMT-like response to transforming growth factor beta and ras oncogenes [40] (and Lyons, unpublished observations). In human breast cancers, heterogeneity of cadherin switching within mammary tumours has been observed, indicating either a sustained diversity of epithelial differentiation status or the occurrence of a reversible EMT [41] . The potential to overlook numerically minor subpopulations of carcinoma cells that have undergone an EMT was demonstrated comprehensively in human breast cancer, in which cells that are phenotypically fibroblasts in almost every way can be generated from malignant mammary epithelial cells through an EMT [42] . It required thorough genetic analyses to be able to distinguish these fibroblast-like cancer cells from normal stromal cells and to establish a carcinoma origin for them. Although the biological properties of the carcinoma-derived fibroblast-like cells were not examined in detail, it is conceivable that they could have combined properties typical of fibroblasts, such as matrix metalloproteinase inducibility, with properties typical of carcinoma cells, such as unlimited proliferation. Another form of plasticity, vasculogenic mimicry [43] may also make it difficult to identify metaplastic cancer cells using conventional histopathological methods.
A number of cell signalling pathways that are activated by genetic alterations common in carcinomas can cause an EMT, including those that operate through ras, src, SMADs, E-box binding repressors (Snails and ZEBs), beta-catenin and NF-kappaB [44] [45] [46] [47] [48] [49] [50] . Many of these pathways produce microenvironmental phenotypes that accompany the EMT, due to changes that they induce in the secretion of growth factors, cytokines, chemokines, lytic enzymes, ECM, etc. Particular characteristics of EMT would be expected to favour the selection of mutations that both give rise to EMT and contribute to clonal diversity in carcinomas. These pro-oncogenic characteristics include increased motility, reduced cellcell contact and inducibility of a broad range of ECMdegrading proteinases, as occurs in the BC1 mammary carcinoma [34] . However, the acquisition of these properties by undergoing an EMT might come with a tradeoff, by losing complementary pro-oncogenic properties e.g. autonomy of proliferation in cells that maintain an epithelial phenotype, through the autocrine secretion of growth factors [33] . Such a loss of complementary properties would occur either if the genetic changes conferring proliferative autonomy are mutually incompatible with the EMT-inducing genes, or if they arise from the deletion or inactivation of a chromosomal region that includes the EMT-inducing genes. In either case, the fastest and most probable way to acquire both complementary mutations in a tumour would be for them to occur in different but nearby cells within the cancer cell population, thereby maintaining both populations of cells: those that maintain an epithelial phenotype and secrete growth factors and those that break down ECM.
When are tumours more likely to progress by interclonal cooperativity than by lineal evolution?
To illustrate the impact that the microenvironmental nature of a phenotype and consequent interclonal cooperativity can have on tumour progression, consider the example in which two mutations are required to cause a tumour to progress to malignancy, and both mutations are independent and equally likely to occur. If the phenotypes arising from both mutations are cell-autonomous and so must occur in the same cell, then progression can only take place through lineal evolution. If, however, one of the mutations produces a microenvironmental phenotype, then progression can take place through either lineal evolution or interclonal cooperativity. To compare the two modes of evolution, we may ask the question: how many instances of two mutations occurring within 10 cell diameters do we expect to occur in a tumour, compared with the two mutations occurring in the same cell? If we assume that the cells are non-deformable, regularly packed spheres in a cubic lattice array, then 5,569 cells will fall within the field of influence (Fig. 3) ; this number will underestimate the case in most real tumours, in which cells are deformable and are likely to have higher packing densities. Now, let the probability of both mutations occurring within the same cell be P LE and the probability of progression proceeding by that mutation occurring in two different cells be P IC . Then P IC = 1 - (1-M) n-1 , where n is the number of cells within the field of influence of the microenvironmental phenotype and M is the mutation frequency. For low mutation rates of 10 -6 to 10 -7 , similar to normal cells [51] , the probability of the mutations occurring anywhere within the field of influence in the next round of cell division will be greater than the probability of them occurring within a single cell by, approximately, the number of other cells within the field of influence. To express it another way, a cancer that arises from a benign tumour by acquiring two low frequency mutations, at least one of which has a microenvironmental range of activity of 10 cell diameters, is 5,568 times more likely to have progressed to malignancy through interclonal cooperativity than through lineal evolution. The likelihood that the cancer will be biclonal, rather than monoclonal, will be correspondingly higher.
The impact of interclonal cooperativity decreases with increasing mutation frequency (Fig. 4) but, even at a very high mutation frequency of 10 -2 , there is still a 100-fold higher expectation that the tumour will progress through interclonal cooperativity for this range of activity. As the range of activity decreases, the likelihood of interclonal cooperativity being responsible for progression also decreases. Nevertheless, even when the microenvironmental phenotype operates over a range of activity of just two cell diameters and appears with a very high mutation frequency of 10 -2 in a low efficiency cubic lattice packing arrangement, there is still a *70-fold bias towards interclonal cooperativity being the mechanism of progression. When interclonal cooperativity requires direct cell-cell contact (i.e. a range of activity of 0 cell diameters) and the mutation that gives rise to it appears with a very high frequency of 10 -2 , there is a *6-fold higher likelihood of progressing through interclonal cooperativity than through lineal evolution under these conditions. This example assumes an almost simultaneous acquisition of both mutations, which may not be the case in vivo. Another limitation is that it does not take into account the relative abundance of genes that can give rise to cellautonomous versus microenvironmental phenotypes. Nevertheless, it illustrates the point that, for mutations that confer a microenvironmental phenotype on cells, progression can occur early through interclonal cooperativity prior to clonal dominance conferred by one of the mutations. Moreover, when both mutations have occurred in two separate but interacting clones, co-dominance of the clones will ensue, producing a polyclonality that is stable, because there will no longer be any selection pressure to drive the tumour towards monoclonality for both mutations. Importantly, unlike lineal evolution, interclonal cooperativity does not rely on the assumption that every mutation on the road to malignancy must confer an advantage on the clone that acquires it over the preceding lineage, thereby leading to clonal dominance. Mutations whose conferral of advantage rely on other mutations, potentially in a mutually reliant way, need not be selected against in interclonal cooperativity, whereas they would be extinguished in a progression model driven by clonal dominance. This would permit a degree of flexibility in the temporal order of acquisition of mutations that could not occur in lineal evolution. This temporal flexibility would itself increase the odds in favour of progression through interclonal cooperativity and has been observed in the progression of Barrett's oesophagus to adenocarcinoma [52] .
There can even be circumstances where the probability of two mutations occurring in the same cell is zero, due to them having mutually incompatible effects on that cell. In these circumstances, the probability of progression through lineal evolution would also be zero-interclonal cooperativity would be mandatory for progression to take place. One such scenario, where the formation of polyclonal tumours would be strongly favoured, is where the effects of two or more mutations that have complementary, prooncogenic, microenvironmental phenotypes are mutually incompatible within a single cell, due to conflicting cellautonomous side-effects. Take, for example, the scenario in which two additional microenvironmental phenotypes are needed for a tumour to progress to malignancy, and mutations in gene A and gene B produce these phenotypes (Fig. 5) . However, the intracellular signalling pathway activated by A has the side-effect of down-regulating the signalling pathway activated by B. In this scenario, cells that are already mutant in A will not acquire a selective advantage by acquiring a mutation in B, because mutation A will counteract the phenotype conferred by mutation B (Fig. 5a) . Not only will the acquisition of the second mutation in the same cell not be selected for, it will be selected against. In contrast, if a mutation in B occurs in a cell within the field of influence of the cell that is mutant for gene A (Fig. 5b) , then it will have a strong selection advantage, because the two mutations will be mutually compatible, due to their locations in different cells, and complementary, due to their distinct microenvironmental effects.
The extensive feedback and cross-talk between prooncogenic signalling pathways make such a scenario not unlikely. An example where this might occur is breast cancer, in which mutations in p53 and PTEN tend to be mutually exclusive within microdissected regions, both in Fig. 4 Tumour progression through mutations with a microenvironmental phenotype is much more likely to occur through interclonal cooperativity than lineal evolution. The mutation frequency and range of activity of a microenvironmental phenotype were adjusted to determine what impact they have on the likelihood that a premalignant tumour progresses by interclonal cooperativity, compared with lineal evolution. The tumour requires two complementary, mutually compatible mutations in order to progress to malignancy, one of which produces a microenvironmental phenotype. The expectation of the mutations occurring in two different cells within the range of activity of that phenotype, relative to them occurring within a single cell (P IC /P LE ), is given by the equation:
where M is the mutation frequency and n is the number of cells within the field of influence. The outcomes for three different ranges of activity are shown. A range of zero means that direct cell-cell contact is required for interclonal cooperativity the epithelial and the stromal compartments [53] ; the possibility that cells within the stromal compartment arose as a result of an EMT was not explored in that study.
Whether the mutual exclusivity of the p53 and PTEN mutations is a result of selection against cells bearing both mutations due to biological incompatibilities between them, or simply a parallel evolution due to redundancy in their effects, is not known. However, the distinct intracellular locations and biochemical activities of these two tumour suppressor genes would make a complete redundancy unlikely.
Evidence for and against lineal evolution and interclonal cooperativity
Support for the acquisition of invasion and metastasis by lineal evolution has come from several investigations that have derived intrinsically metastatic clones from polyclonal tumour populations. A clone is intrinsically invasive or metastatic if it is self-sufficient for all of the requirements for invasion or metastasis, in the absence of other clones, as would be expected to result from lineal evolution. Using lung colonization by injected B16 mouse melanoma cells as a model, it was demonstrated that an intrinsically highly metastatic cell line could be derived from a less metastatic cell line by repeated cycles of metastasis i.e. by re-injecting cells derived from metastases [54] [55] [56] [57] . Other studies [58] [59] [60] suggested that selection of metastatic cells can occur even within the primary tumour and come to dominate it. Although the B16 melanoma and similar models [61] have been very useful for studying certain aspects of metastasis, they differ from human cancers, in which metastases do not arise from metastatic cycling. The number of population doublings in which mutations can take place and the amount of time spent under selection pressures is obviously greater in the cells selected from 10 cycles of metastasis than in an original primary tumour. Correspondingly, the mechanisms of metastasis that evolve after 10 previous cycles of metastasis may be quite different from those of the original primary tumour. Thus, although the B16 melanoma studies showed that intrinsically metastatic clones can be selected for by metastatic cycling, it does not necessarily follow that intrinsically metastatic cells do make the dominant contribution to metastatic burden originating from a primary tumour. Even in the B16 melanoma model, polyclonality in metastases has been demonstrated, and done so using relatively insensitive methods that may have missed minor clonal populations [62] . Moreover, in addition to the data in Fig. 2 , several studies have challenged the generality of the idea that the metastatic phenotype is selected for in clones of the primary tumour or even in metastases [63] [64] [65] [66] . Thus, the literature indicates that metastatic clones are sometimes selected for in a way consistent with a lineal evolution model of progression, and sometimes they are not. One explanation offered to reconcile the lineal evolution model with this frequent inability to detect selection of a highly metastatic phenotype in metastases is that a cell acquires an intrinsic metastatic phenotype and then, following metastasis, loses it due to a high rate of genetic instability [67, 68] . An alternative explanation is that, similar to the situation in the BC1 system, there are subpopulations of cells within the primary tumour that take part in the metastatic process by facilitating metastasis of other subpopulations, but that do not themselves metastasise. 5 Malignancy requiring mutually incompatible mutations can only progress through interclonal cooperativity. A pre-malignant lesion requires two more mutations that have microenvironmental phenotypes in order to progress to malignancy. However, the mutation in gene A also has the cell-autonomous phenotype of blocking the phenotype caused by the mutation in gene B. If both mutations occur in the same cell, as depicted in (a), progression will not occur, because the cell will only display phenotype A. However, if the mutations occur in two different cells within the range of activity of both microenvironmental phenotypes (b), then progression will occur, because both cells will be subject to both phenotypes Apart from the studies in the BC1 system described above, there is other evidence for interactions occurring between phenotypically distinct clones of tumour cells. Multiclonal interactions can cause the stabilization of the metastatic phenotype [55] , growth suppression [69, 70] , the transmission of drug resistance [71, 72] and lung colonization following intravenous injection [73] . In the lastmentioned study, a cell line with no intrinsic metastasising ability was found to accumulate in metastases, provided that an intrinsically metastatic cell line was co-injected. An investigation of Kaposi's sarcoma herpes virus showed that tumour size and incidence increased when vGPCR-transformed endothelial cells were co-administered with endothelial cells that had been transfected with other viral genes, consistent with the mosaic pattern of expression of these genes in human Kaposi sarcomas [74] . A recent study of Barrett's oesophagus [75] , a pre-malignant condition in which stratified squamous epithelium transdifferentiates into glandular epithelium, demonstrated a correlation between high genetic diversity and progression to adenocarcinoma-more homogeneous tumours were less likely to progress. Although it was postulated in that paper that the contribution of polyclonality to progression was passive, merely providing a greater diversity of clones from which to select, it is also consistent with cancer cell-cancer cell interactions driving progression.
Tumour cell diversity: a case for mathematical modelling to help understand its implications and make predictions of tumour behaviour Mathematical modelling is becoming increasingly important in cancer research to 'elucidate the fundamental mechanisms of cancer progression and either to improve the therapeutic techniques currently used or to stimulate the development of new strategies' [76] . The advantages that mathematical modelling brings to the field of tumour growth are two-fold. First, models foster greater insights into the underlying dynamics of a system, especially in complex systems such as carcinogenesis where the dynamics are not readily apparent. Second, simulations can give a preliminary guide to experimental research. Here we focus on the former and discuss models that explore the effects of loss of cell adhesion and of increased cell motility. These are two important characteristics of cells undergoing EMT.
Various mathematical models have been created in which the role of cell adhesion in tumour progression has been studied. Many of these models examine a heterogeneous cell population, which is consistent with experimental findings. In all of these models, however, the underlying assumption is that the mutation sequence is linear, so that cells do not undergo interclonal cooperativity; different cell lineages are considered to be in competition, never in cooperation. Recent examples [77] [78] [79] have implicated nutrient depletion as a driving force for invasion. In his model [78] , Anderson considered a heterogeneous cell population in ECM that is homogeneous, heterogeneous or randomly distributed. The behaviour of the system was examined when there were four as well as 100 different phenotypes, each with different levels of cell adhesion. Although different cancer cell phenotypes were considered, cooperation towards malignancy was not. The results of the model showed that similar patterns of progression were obtained in the case of four as well as 100 phenotypes, suggesting that useful analysis can be carried out without needing to incorporate a large number of phenotypes.
Models with a small number of phenotypes have an advantage in the study of interclonal cooperativity because of the rapid growth of the number of cell-cell interactions with the number of phenotypes. In fact, for every n phenotypes in a tumour, there are of the order of n 2 different cell-cell interactions. Hence it is desirable to use the smallest appropriate number of phenotypes in the model. Such a model would be computationally tractable while still exhibiting behaviour unique to interclonal cooperativity and reflecting the complexity observed in experimental findings.
Analysis of cell-cell interactions in cancer could be enhanced further through the study of cell sorting behaviour. Experiments by Steinberg [80, 81] showed that a heterogeneous mixture of embryonic cells reverted to particular configurations, regardless of the initial configuration. While it is possible that not all cell types behave similarly, aptly chosen phenotypes may be chosen that exhibit this behaviour. Thus, analysis of interclonal cooperativity could be systematically simplified to the limited configurations that occur.
A model developed by Armstrong et al. [82] based on cell adhesion captures this behaviour. In the model, two interacting populations are considered including both selfpopulation adhesion as well as cross-population adhesion. Interclonal cooperativity can be thought of as an advance of this phenomenon. Instead of two phenotypes merely coexisting in equilibrium, the different phenotypes cooperate to drive tumour progression.
Another characteristic of EMT is an increase in cell motility. Despite recent efforts such as the introductory paper by Coskun et al. [83] , which underlines the importance of cell motility in progression towards malignancy, this field of study is relatively unexplored (reviewed in [84] ). Indeed, modelling has the potential to be particularly useful in the study of cell motility because mechanisms of cell movement are complicated and experiments may be expensive and difficult. In this context mathematical models may provide insight into cell behavior and help with the analysis and interpretation of experimental data [83] .
In this paper, we provide a simple introductory model that illustrates the effect of interclonal cooperativity as a driving force in tumour progression. The development of mathematical models that include both the loss of cell adhesion and increased cell motility will be important in the study of interclonal cooperativity, as both of these factors play an important role in the path towards malignancy. In the future, clonal analysis of oncogene expression in tumour specimens, together with mathematical modelling, may be used to devise improved therapies for treating cancer, by taking into account the diversity of cellular phenotypes and the complexity of cell-cell interactions that occur in malignant tumours.
